The action during the premarket trading period often gives a fair idea of the way the market is going to go for the rest of the day and this morning, the Galectin Therapeutics Inc (NASDAQ: GALT) stock has emerged as a notable gainer.
The stock has surged by 27% this morning and the rise is possibly linked to a major announcement made by the company yesterday. Galectin announced yesterday that a paper published in the noted medical journal named Journal for ImmunoTherapy of Cancer described the results from the Phase 1 clinical study of one of the company’s projects.
The study is a joint effort from Galectin and the Providence Cancer Institute that operated out of Portland in Oregon. The results were positive and the publication of the same in the highest-ranked journal with regards to open access immunology is a significant boost for Galectin. Investors could consider keeping track of this stock today.
Writing for business and finance publishers has become his passion over the last decades after he completed a master’s degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.